Clinuvel Pharmaceuticals (ASX:CUV) has enrolled more than 200 patients in its phase III trial of Scenesse in vitiligo in line with its recruitment target, according to a Wednesday filing with the Australian bourse.
The randomized trial is being conducted in 37 study sites across North America, Africa, and Europe. It is assessing Scenesse as a systemic repigmentation therapy for vitiligo patients using the vitiligo area scoring index as the primary endpoint, the filing said.
The trial aims to achieve a minimum of 50% repigmentation across a patient's total body surface area, the filing added. Initial results are expected in the second half of 2026.
Clinuvel Pharmaceuticals' shares were down nearly 1% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.